Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction
- PMID: 9741514
- DOI: 10.1016/s0735-1097(98)00297-6
Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction
Abstract
Objective: This study undertook to determine if the presence of atrial fibrillation in patients with asymptomatic and symptomatic left ventricular dysfunction was associated with increased mortality and, if so, whether the increase could be attributed to progressive heart failure or arrhythmic death.
Background: Atrial fibrillation is a common condition in heart failure with the potential to impact hemodynamics and progression of left ventricular systolic dysfunction as well as the electrophysiologic substrate for arrhythmias. The available data do not conclusively define the effect of atrial fibrillation on prognosis in heart failure.
Methods: A retrospective analysis of the Studies of Left Ventricular Dysfunction Prevention and Treatment Trials was conducted that compared patients with atrial fibrillation to those in sinus rhythm at baseline for the risk of all-cause mortality, progressive pump-failure death and arrhythmic death.
Results: The patients with atrial fibrillation at baseline, compared to those in sinus rhythm, had greater all-cause mortality (34% vs. 23%, p < 0.001), death attributed to pump-failure (16.7% vs. 9.4%, p < 0.001) and were more likely to reach the composite end point of death or hospitalization for heart failure (45% vs. 33%, p < 0.001), but there was no significant difference between the groups in arrhythmic deaths. After multivariate analysis, atrial fibrillation remained significantly associated with all-cause mortality (relative risk [RR] 1.34, 95% confidence interval [CI] 1.12 to 1.62, p=0.002), progressive pump-failure death (RR 1.42, 95% CI 1.09 to 1.85, p=0.01), the composite end point of death or hospitalization for heart failure (RR 1.26, 95% CI 1.03 to 1.42, p=0.02), but not arrhythmic death (RR 1.13; 95% CI 0.75 to 1.71; p=0.55).
Conclusions: The presence of atrial fibrillation in patients with asymptomatic and symptomatic left ventricular systolic dysfunction is associated with an increased risk for all-cause mortality, largely explained by an increased risk for pump-failure death. These data suggest that atrial fibrillation is associated with progression of left ventricular systolic dysfunction.
Similar articles
-
Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction.J Am Coll Cardiol. 1999 Mar 15;33(4):916-23. doi: 10.1016/s0735-1097(98)00675-5. J Am Coll Cardiol. 1999. PMID: 10091816 Clinical Trial.
-
The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.J Am Coll Cardiol. 2000 Mar 1;35(3):681-9. doi: 10.1016/s0735-1097(99)00608-7. J Am Coll Cardiol. 2000. PMID: 10716471 Clinical Trial.
-
Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.Eur J Heart Fail. 2014 Mar;16(3):325-33. doi: 10.1002/ejhf.23. Epub 2014 Jan 23. Eur J Heart Fail. 2014. PMID: 24464788 Clinical Trial.
-
Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart failure.Eur Heart J. 1995 Dec;16 Suppl N:59-64. doi: 10.1093/eurheartj/16.suppl_n.59. Eur Heart J. 1995. PMID: 8682063 Review.
-
Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use.Eur Heart J. 1995 Dec;16 Suppl N:65-72. doi: 10.1093/eurheartj/16.suppl_n.65. Eur Heart J. 1995. PMID: 8682064 Review.
Cited by
-
Clinical Outcomes of Rhythm Control Strategies for Asymptomatic Atrial Fibrillation According to the Quality-of-Life Score: The CODE-AF (Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation) Registry.J Am Heart Assoc. 2022 Sep 20;11(18):e025956. doi: 10.1161/JAHA.122.025956. Epub 2022 Sep 8. J Am Heart Assoc. 2022. PMID: 36073646 Free PMC article.
-
Short- and long-term risk of atrial fibrillation recurrence after first time ablation according to body mass index: a nationwide Danish cohort study.Europace. 2023 Feb 16;25(2):425-432. doi: 10.1093/europace/euac225. Europace. 2023. PMID: 36480430 Free PMC article.
-
Atrial Fibrillation on Intensive Care Unit Admission Independently Increases the Risk of Weaning Failure in Nonheart Failure Mechanically Ventilated Patients in a Medical Intensive Care Unit: A Retrospective Case-Control Study.Medicine (Baltimore). 2016 May;95(20):e3744. doi: 10.1097/MD.0000000000003744. Medicine (Baltimore). 2016. PMID: 27196499 Free PMC article.
-
Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation.Europace. 2010 Jan;12(1):24-9. doi: 10.1093/europace/eup309. Europace. 2010. PMID: 19880855 Free PMC article. Clinical Trial.
-
Acute management of atrial fibrillation and atrial flutter in the critical care unit: should it be ibutilide?Clin Cardiol. 2000 Apr;23(4):265-8. doi: 10.1002/clc.4960230408. Clin Cardiol. 2000. PMID: 10763074 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical